Department of Thoracic Surgery, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Imaging Institute of Italian Switzerland (IIMSI), Ente Ospedaliero Cantonale, Via Tesserete 46, 6900 Lugano, Switzerland.
Curr Oncol. 2024 Nov 2;31(11):6867-6878. doi: 10.3390/curroncol31110507.
Malignant pleural effusion is the presence of malignant cells within the pleural fluid, representing the second most common cause of pleural exudate. Although diagnostic methods and management techniques for malignant pleural effusion have dramatically improved over the decades, the current treatment is still palliative, aiming to remove pleural fluid, possibly prevent its recurrence, and alleviate symptoms through a wide range of available procedures. Treatment should be tailored to the individual patient, considering comorbidities, size of the effusion, rate of fluid accumulation, underlying cardiac or respiratory conditions, rate of recurrence, presence of loculations or trapped lung, tumor characteristics, cancer type, and patient preferences. This manuscript aims to review the available literature and to present the latest evidence on malignant pleural effusion management in order to provide an updated perspective on its diagnosis and treatment.
恶性胸腔积液是指胸腔积液中存在恶性细胞,是胸腔渗出液的第二大常见原因。尽管几十年来恶性胸腔积液的诊断方法和治疗技术有了显著的提高,但目前的治疗仍然是姑息性的,旨在通过各种可用的方法来清除胸腔积液、可能预防其复发,并缓解症状。治疗应根据患者的个体情况进行调整,考虑合并症、胸腔积液的大小、积液积累的速度、基础心脏或呼吸状况、复发率、有无分隔或肺不张、肿瘤特征、癌症类型以及患者的偏好。本文旨在回顾现有文献,并呈现恶性胸腔积液管理的最新证据,以期对其诊断和治疗提供新的视角。